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ABSTRACT
Introduction Recurrent pulmonary exacerbations 
lead to progressive lung damage in cystic fibrosis (CF). 
Inhaled medications (mucoactive agents and antibiotics) 
help prevent exacerbations, but objectively measured 
adherence is low. We investigated whether a multi- 
component (complex) self- management intervention to 
support adherence would reduce exacerbation rates over 
12 months.
Methods Between October 2017 and May 2018, 
adults with CF (aged ≥16 years; 19 UK centres) 
were randomised to the intervention (data- logging 
nebulisers, a digital platform and behavioural change 
sessions with trained clinical interventionists) or usual 
care (data- logging nebulisers). Outcomes included 
pulmonary exacerbations (primary outcome), objectively 
measured adherence, body mass index (BMI), lung 
function (FEV
1) and Cystic Fibrosis Questionnaire- 
Revised (CFQ- R). Analyses were by intent to treat over 
12 months.
Results Among intervention (n=304) and usual care 
(n=303) participants (51% female, median age 31 
years), 88% completed 12- month follow- up. Mean 
exacerbation rate was 1.63/year with intervention and 
1.77/year with usual care (adjusted ratio 0.96; 95% 
CI 0.83 to 1.12; p=0.64). Adjusted mean differences 
(95% CI) were in favour of the intervention versus usual 
care for objectively measured adherence (9.5% (8.6% 
to 10.4%)) and BMI (0.3 (0.1 to 0.6) kg/m2), with no 
difference for %FEV1 (1.4 (−0.2 to 3.0)). Seven CFQ- R 
subscales showed no between- group difference, but 
treatment burden reduced for the intervention (3.9 (1.2 
to 6.7) points). No intervention- related serious adverse 
events occurred.
Conclusions While pulmonary exacerbations and 
FEV1 did not show statistically significant differences, 
the intervention achieved higher objectively measured 
adherence versus usual care. The adherence difference 
might be inadequate to influence exacerbations, though 
higher BMI and lower perceived CF treatment burden 
were observed.
INTRODUCTION
Cystic fibrosis (CF) is a multisystem genetic long- 
term condition (LTC) whereby recurrent pulmo-
nary exacerbations drive progressive lung damage 
leading to premature death. Inhaled mucoactive 
agents and antibiotics have proven efficacy in 
reducing exacerbation frequency.1 2 CF is therefore 
an archetypal LTC; a cure is unavailable though 
efficacious treatments exist to improve health 
outcomes.
Low medication adherence, described by the 
WHO as ‘a worldwide problem of striking magni-
tude’3 is an important cause of treatment failure, 
poor health outcomes and increased healthcare 
costs in LTCs. In CF, low adherence to inhaled ther-
apies is associated with more frequent and costly 
rescue treatments of exacerbations.4 Real- world 
Key messages
What is the key question?
 ► Can a multi- component self- management 
intervention increase and sustain adherence 
to inhaled therapies among adults with cystic 
fibrosis (CF) and does the intervention impact 
on exacerbation rates?
What is the bottom line?
 ► The intervention did not show a statistically 
significant difference in exacerbation rates 
versus usual care but achieved higher 
objectively measured adherence to inhaled 
medications (sustained over 12 months), higher 
body mass index and lower perceived CF 
treatment burden.
Why read on?
 ► This is the largest self- management 
intervention trial in CF, with 607 participants, 
and the only trial thus far to demonstrate a 
sustained difference in adherence versus a 
control arm, using a theory- based approach 
including habit formation.












































































































































































































































































































































































































































































































































































































































































































































































































































































































objectively measured adherence of 30%–50% is lower than 
that of 80%–100% usually observed in clinical trials.5 There-
fore, people with CF are unlikely to derive optimal benefit from 
inhaled therapies.5–10 At the same time, perceived treatment 
burden is high among people with CF11 and the James Lind 
Alliance Priority Setting Partnership identified ‘effective ways of 
simplifying treatment burden’ as the top CF research priority.12
Developing strategies to increase adherence is another CF 
research priority12 and could improve health outcomes by 
reducing exacerbation rates.6 Insufficient evidence exists to 
promote any particular adherence strategy.13 Large randomised 
controlled trials evaluating adherence interventions in CF 
continue to present negative findings,14 possibly because inter-
ventions are generally under- theorised and insufficiently tailored 
to individual needs.15 In addition, objectively measured adher-
ence is largely absent in routine CF care, while self- reported 
and clinician estimates of adherence are notoriously unreliable,8 
which prevents effective diagnosis, prescribing and provision of 
person- specific adherence support.
The Capability Opportunity Motivation- Behaviour model, 
based on a synthesis of frameworks of behavioural change, 
predicts that treatment taking depends on capability, opportunity 
and motivation.16 Reflective motivation is largely dependent on 
perceived necessity of adherence and treatment concerns17 and 
can be increased through education, persuasion and confidence 
building. For those motivated to adhere, increasing awareness 
of their objectively measured adherence through self- monitoring 
increases capability, that is, making visible the gap between 
objective and subjective adherence.8 Problem- solving techniques 
can be used to overcome individual capability and opportunity 
barriers. Theories of behavioural maintenance18 predict that 
supporting people to create habits for treatment, that is, taking 
treatments in response to specific contextual cues, can help to 
sustain adherence and to lower perceived treatment burden.19 
We developed a multi- component (complex) self- management 
intervention to support sustained treatment adherence,20 incor-
porating objective adherence measurement, underpinned by 
behavioural science theory and designed to address gaps in CF 
care, with extensive input from people with CF. Since exacerba-
tions are disruptive to patient life, they are an important patient- 
centred outcome and are commonly considered to indicate lung 
health.21 Therefore, the objective of this 12- month randomised 
controlled trial was to investigate the effectiveness of this multi- 
component self- management intervention compared with usual 
care in adults with CF using pulmonary exacerbation incidence 
rate as the primary outcome.
METHODS
Study design, clinical interventionists and participants
We conducted a two- arm, open- label, parallel- group, usual 
care- controlled randomised clinical trial at 19 UK CF centres 
(trial registration ISRCTN55504164). The protocol (ethical 
approval REC: 17/LO/0035, IRAS ID: 218519) and statistical 
Table 1 Description of the intervention
TIDieR category Description of the CFHealthHub intervention
  CFHealthHub digital platform (website and smartphone application) that: (1) displays real- time objective adherence data from the nebulisers to 
the participant and care team, (2) provides behavioural change tools and content (comprises of six modules, see 1)) in a ‘My Toolkit’ area designed 
to increase motivation for adherence, to address capability and opportunity barriers and to build habits for taking treatments, and (3) includes an 
intervention manual, with procedures and worksheets for use by clinical interventionists in their interactions with participants.
Behaviour change sessions where the content and behaviour change techniques within each of the six modules were delivered through the participant 
interactions with site’s interventionist.
Why CFHealthHub aims to support adults with CF to increase adherence to nebuliser treatment using the COM- B framework and to build habits for treatment 
to enable maintenance.
Who Interventionists were healthcare professionals employed for the trial (n=32),
18 of whom job shared (with clinical roles in the CF team) and 26 were existing members of the centre’s CF multidisciplinary team. There was the WTE of 
eight physiotherapists, three psychologists, six specialist CF nurses, one pharmacist and one dietitian; that is, one WTE interventionist per centre.
How and where All intervention sessions were structured by a worksheet to guide delivery and delivered with a person- centred communication style. First intervention 
sessions were always face to face; review sessions were face to face or by telephone.
When and how much Intervention participants had access to the digital platform and received tailored flexible support from the interventionist throughout the 12- month trial 
period. All intervention participants received a first and intermediate review visit, thereafter support was tailored according to response (figure 1; further 
details in online supplemental 1appendix A).
Participants with baseline objectively measured effective adherence ≤80% underwent a normal pathway of six sessions (1× first intervention visit 
40–60 min; 2× intermediate reviews 5–15 min; 2× reviews 30–45 min; 1× phase review 20–30 min) over 12 weeks, with phase reviews every 12 weeks 
thereafter, or every 6 weeks for participants with baseline adherence <25%.
Participants with baseline objectively measured effective adherence >80% followed a ‘very high adherence’ pathway of three sessions (1× first 
intervention visit; 1× intermediate review; 1× phase review), with phase reviews every 12 weeks thereafter.
Following these initial pathways, additional blocks of sessions were offered when: (1) a participant requested further support; (2) a participant’s 
adherence reduced by ≥20% in a 4- week period; or (3) a participant received intravenous antibiotics for an exacerbation.
Tailoring Each session was tailored to an individual’s needs based on: their nebulised medication prescription; their necessity and concern beliefs (BMQ- Specific); 
and their discussions with interventionists about their motivation and specific capability and opportunity barriers to adherence. For example, the goal 
setting and review and treatment plan modules are used only for participants who are motivated to increase their treatment adherence and participants 
with very low motivation spend more time focusing on the my treatment module and on relationship building with the interventionist.
While the entire content of the digital platform was available for participants to browse, tailored/personalised aspects were added to the ‘My Toolkit’ 
area. For example, content addressing particular participant concerns about treatment, and personal action and coping plans.
Modifications There were no major changes to the delivery of the intervention through the study.
How well Fidelity of intervention delivery was assessed throughout the study with two reviewers independently assessing a sample of audio- recording and 
worksheets from sessions (first intervention session, review, phase review) using a scoring sheet (further details in online supplemental appendix A).
BMQ- Specific, beliefs and medications questionnaire- specific; CF, cystic fibrosis; COM- B, capability opportunity motivation- behaviour; TIDieR, template for intervention description 
and replication; WTE, whole time equivalent.





















analysis plan (SAP) are available as supplementary material. The 
complex behavioural change intervention is designed to increase 
and sustain adherence to inhaled therapies. The development of 
the intervention is described elsewhere.22 Table 1 summarises the 
intervention, and further descriptions are in online supplemental 
appendix A. The study was monitored by an independent Trial 
Steering Committee. Data analysis was performed by the School 
of Health and Related Research, Sheffield. All authors vouch for 
fidelity to the protocol.
Full- time interventionists (table 1) were employed and trained 
to deliver the intervention, underwent competency assessments 
(a theory test; practical assessments at first intervention visit, 
review and phase review) and received ongoing support (as 
detailed in online supplemental appendix A).
Participants were identified from the CF Registry, a UK data-
base of people with CF. Potential participants were contacted by 
their usual clinical care team to seek permission for intervention-
ists to discuss involvement. Eligible participants were aged ≥16 
years and willing to take all inhaled mucoactive agents and 
antibiotics via eFlow Technology nebulisers with eTrack data- 
logging Controllers (PARI Pharma GmbH, Starnberg, Germany). 
Participants were excluded if: on the active lung transplant list; 
post- lung transplant; receiving care primarily palliative in intent; 
or using inhaled dry powder devices. All participants provided 
written, informed consent.
Randomisation and masking
Participants were allocated 1:1 to the intervention or usual care 
using a computer- generated pseudorandom list with random- 
permuted blocks of randomly varying sizes, via a central, web- 
based randomisation system. The allocation sequence was 
hosted by the Sheffield Clinical Trials Research Unit, with the 
sequence created by a statistician (not otherwise involved with 
trial) and held on a secure server. After recruiting each partici-
pant, the interventionist logged into the server and entered basic 
demographic information, then the allocation was revealed to 
the participants. Stratification was by centre and number of past 
year intravenous antibiotic days (≤14 and >14) – a predictor of 
current year intravenous days.23 The trial statistician remained 
blind to treatment allocation until database freeze. Participants 
and health professionals collecting primary outcome data were 
not blinded.
Treatment arms
All participants were given eTrack data- logging Controllers for 
their eFlow Technology nebulisers, which sent time- stamped 
and date- stamped data to a 2net Hub (Capsule Technologies, 
San Diego, California, USA) for accurate recording of inhalation 
and adherence calculation.
Intervention participants had access to the CFHealthHub 
digital platform (website and smartphone application) and 
received tailored flexible support from the interventionist 
throughout the 12- month trial period (table 1 and figure 1; 
further details in online supplemental appendix A).
The usual care arm used eTrack data- logging Controllers for 
adherence data collection. Contamination was minimised since 
there was no access to CFHealthHub, behavioural change tools 
and content. Adherence results were also invisible to participants 
and care teams.
At the final visit (at 12 months) or when a participant dropped 
out in either arm, a systems check was performed to ensure 
that all adherence data had been transferred from the eTrack 
data- logging Controller, thereby minimising missing data. The 
eTrack can store 3000 inhalations, which exceed the annual total 
number of doses even when the maximum prescription of eight 
daily doses occurred (table 2 gives prescribed doses), ensuring no 
missing data if eTrack was downloaded at the end of trial.
Outcomes
The primary outcome was the pulmonary exacerbation inci-
dence rate over 12 months. Using modified Fuchs’ criteria,24 an 
Figure 1 Schedule of intervention delivery: normal and ‘very high adherence’ pathways. Adherence level to reflect baseline was calculated using 
objectively measured effective adherence data from weeks 1 and 2, as stated in the ‘Methods’.





















Table 2 Baseline demographic and clinical characteristics, by randomised treatment group
Usual care Intervention
N* Mean±SD† N* Mean±SD†
Female, n (%) 303 154 (50.8) 304 156 (51.3)
Age, years 303 30.3±10.8 304 31.1±10.6
Prescribed number of daily nebuliser doses, n (%)
  1 298 60 (20.1) 303 85 (28.1)
  2 298 49 (16.4) 303 39 (12.9)
  3 298 93 (31.2) 303 91 (30.0)
  4 298 38 (12.8) 303 32 (10.6)
  5 298 38 (12.8) 303 3 (10.9)
  6 298 9 (3.0) 303 10 (3.3)
  ≥7 298 11 (3.7) 303 13 (4.3)
Socioeconomic deprivation quintiles, n (%)
  1 (least deprived) 302 51 (16.9) 302 50 (16.6)
  2 302 71 (23.5) 302 59 (19.5)
  3 302 66 (21.9) 302 63 (20.9)
  4 302 67 (22.2) 302 63 (20.9)
  5 (most deprived) 302 47 (15.6) 302 67 (22.2)
Pseudomonas aeruginosa status, n (%)‡
  Chronic 299 175 (58.5) 304 174 (57.2)
  Non- chronic 299 124 (41.5) 304 130 (42.8)
  Previous year’s intravenous treatment, days 303 27.7±33.0 304 24.2±27.9
Secondary outcomes: baseline values
  Objectively measured effective adherence (weekly), %§ 295 45.5±34.1 293 54.1±33.0
  FEV1 % predicted 302 58.3±22.6 304 60.7±23.5
  Body mass index, kg/m2 303 22.5±4.2 304 22.7±4.2
Patient- reported outcomes: baseline values
CFQ- R (quality of life):
  Physical 302 53.0±30.2 304 54.3±30.6
  Emotional 302 66.2±24.1 304 66.5±21.6
  Social 302 60.9±20.9 304 61.9±20.0
  Eating 302 80.5±24.3 304 82.1±22.5
  Body image 302 66.1±29.3 304 65.6±28.0
  Treatment burden 302 51.8±20.2 304 54.4±19.8
  Respiratory 302 56.6±21.9 304 58.2±22.1
  Digestion 302 81.1±19.4 304 79.9±21.5
BMQ- Specific (beliefs about medication):
  Concerns 301 2.1±0.5 304 2.1±0.6
  Necessities 301 3.6±0.8 304 3.6±0.7
  SRBAI (habit strength for using nebuliser) 300 12.0±4.7 303 12.1±5.0
  Perceptions of treatment adherence (three- item scale) 274 9.9±3.4 280 10.2±3.4
  Effort of nebuliser treatments (one item) 300 3.1±1.2 302 3.1±1.3
  Subjective adherence question
  – % (self- report estimate of adherence)
298 69.0±30.8 300 69.9±31.0
  CHAOS-6 (life chaos or routine) 300 9.5±2.9 303 9.5±2.9
  PAM-13 (health style assessment) 302 65.3±13.3 304 65.8±14.5
  EQ- 5D- 5L (generic health status) 300 0.84±0.16 303 0.85±0.15
  PHQ-8 (depression) 301 6.4±5.1 304 6.4±5.2
  GAD-7 (anxiety) 302 4.7±4.7 302 4.6±4.9
Full details and references for all patient- reported outcomes are available in the SAP (provided in online supplemental material).
*There were 608 participants randomised but one participant randomised to the intervention arm withdrew on the day of consent prior to baseline data collection, giving a maximum n=607 for baseline summaries.
†Unless otherwise stated.
‡Consensus definition.
§Weekly objectively measured effective adherence (sum of doses taken/sum of doses prescribed).
¶All patient- reported outcomes based on points, unless otherwise stated. For direction of positive effect and possible range, see table 3.
BMQ, Beliefs About Medicines Questionnaire; CHAOS-6, Confusion, Hubbub and Order six- item Scale; EQ- 5D- 5L, EuroQol 5- dimension and 5- level; GAD-7, Generalised Anxiety Disorder seven- item scale; PAM-13, Patient Activation 13- item 
Measure; PHQ-8, Patient Health Questionnaire eight- item depression scale; SAP, statistical analysis plan; SRBAI, Self- Report Behavioural Automaticity Index.





















exacerbation occurred if intravenous antibiotics were adminis-
tered for any one of 12 prespecified symptoms. Exacerbation 
forms were completed by a healthcare professional (clinical team 
or interventionist), and documented assessments were conducted 
at each clinical encounter (generally every 3 months) determined 
whether a participant was displaying an exacerbation.
To reflect effective medication use, adherence was calculated 
as normative (effective) adherence9 10 using objective data from 
weeks 3–52 as the outcome and weeks 1 and 2 as the ‘baseline’. 
Objectively measured effective adherence was calculated daily as 
a composite of all inhaled medications then aggregated weekly 
for analysis (appendix B), as we have detailed elsewhere.9 10 Other 
secondary endpoints were percent predicted FEV1), measured at 
each clinical encounter, and body mass index (BMI), calculated 
at baseline and 12 months. Patient- reported outcomes collected 
at baseline and 12 months included: CF Questionnaire- Revised 
(CFQ- R; eight subscales), measuring quality of life and including 
a perceived CF treatment burden subscale; Beliefs About Medi-
cines Questionnaire (BMQ)- specific concerns and necessities; 
Self- Report Behavioural Automaticity Index (SRBAI), measuring 
habit strength; perceptions of treatment adherence (three- item 
scale); perceived effort of nebuliser treatments (one item); 
subjective adherence (self- reported % adherence); Confusion, 
Hubbub and Order 6- item Scale (CHAOS-6); Patient Activa-
tion 13- item Measure (PAM-13); and EuroQol 5- dimension and 
5- level generic health status. Patient Health Questionnaire eight- 
item depression scale and Generalised Anxiety Disorder seven- 
item scale (GAD-7) were safety measures to understand whether 
the intervention worsens depression or anxiety. Adverse events 
were recorded using case report forms and were categorised as 
whether or not expected in relation to medications, or common 
among people with CF. Full details and references for outcomes 
are in the protocol and SAP.
Statistical analysis
Power calculations (online supplemental table 1) informed the 
choice of pulmonary exacerbation as the primary outcome and 
individual (vs cluster) randomisation. Cluster trials are compli-
cated by recruitment bias. While contamination that reduces 
effect size may be a risk with individual randomisation, this can 
usually be overcome by increasing the sample size, which often 
still requires a smaller sample than cluster randomisation.25 The 
sample size was predicted based on reducing two exacerbations 
per year to 1.5 per year (equivalent to an incidence rate ratio of 
2.0/1.5=0.75). Assuming a mean difference of 0.5 pulmonary 
exacerbations between the intervention and usual care arms over 
12 months, an SD of 1.5, a design effect of 1.16 to allow for 
any clustering of outcomes by centre (intraclass correlation 0.01; 
cluster size 17) and an attrition rate of 20%, 556 participants 
were required to provide 90% power at a two- sided 5% level of 
significance.
Baseline characteristics were reported descriptively using 
summary statistics. The primary outcome incidence rate ratio, 
95% CI and p value were estimated using a negative binomial 
regression model, with a random effect to adjust for clustering by 
centre. Log follow- up time was an offset in the model, and past 
year intravenous days (≤14 and >14 days) and treatment arm 
were fixed effects. Details of the sensitivity analyses performed 
on the primary outcome data (including adjustment for missing 
data) are in the SAP. Objectively measured effective adherence 
was analysed using a linear mixed- effects model, with random 
slopes and intercepts; treatment arm, time in weeks, baseline 
adherence (measured in the first 2 weeks post randomisation) 
and past year intravenous days were fixed effects. Treatment 
effects and 95% CI for all other secondary outcomes were 
produced using a mixed- effects model adjusting for baseline and 
past year intravenous days and with a random effect to adjust for 
clustering by centre. To aid interpretation, standardised effect 
sizes (Cohen’s d) were calculated for all secondary outcomes by 
dividing treatment effect with pooled SD
All analyses were prespecified and performed by intent to 
treat using R software V.3.6.1 and SAS V.9.4. CI widths were not 
corrected for multiplicity.
RESULTS
Between October 2017 and May 2018, 3510 adults with CF 
were screened, with 608 enrolled and randomised (interven-
tion n=305; usual care n=303) and 556 declined participation 
(figure 2). Participant recruitment is discussed in appendix C. 
One participant randomised to intervention withdrew on the 
day of consent prior to baseline data collection, thus was not 
included in analyses. The last recruited participant was followed 
until 30 June 2019, when the trial ended. Baseline demographic 
and clinical characteristics are in table 2. The intervention group 
Figure 2 Trial profile. *Exclusions due to missing covariates. 
†Adherence level to reflect the effect of intervention was calculated 
using objectively measured effective adherence data from week 3 (ie, 
from the point of intervention delivery) through to week 52 (ie, the end 
of the trial), as stated in the ‘Methods’ and ‘Results’. The intervention 
effect is best reflected by the cumulative adherence level throughout 
the trial period, similar to the approach of calculating cumulative 
exacerbation events throughout the trial. Though there were drop- outs 
during the trial, exacerbation data were available for all participants 
(expect for a participant who withdrew on the day of randomisation) 
since exacerbation events prior to drop- out were analysed. In a 
similar vein, adherence data available prior to the point of drop out 
were analysed as long as adherence data from week 3 onwards were 
available. Only 19 participants did not provide any adherence data from 
week 3 onwards, that is, adherence data were missing for outcome 
analysis among 19/607 (3%) of participants. Week- by- week breakdown 
of adherence data completeness is provided in online supplemental 
table 2.





















was slightly older, with slightly higher FEV1, slightly lower past 
year intravenous days and slightly higher baseline objectively 
measured effective adherence (measured 2 weeks post rando-
misation)—this imbalance is explored in appendix D. Primary 
outcome data were available for all participants; adherence data 
were missing for 3.1% (19/607) of participants as explained in 
figure 2. Week- by- week breakdown of adherence data complete-
ness is in online supplemental table 2.
The median (IQR) number of interventionist sessions per 
participant was 7.0 (6.0–10.0). The median (IQR) total interven-
tionist delivery time per participant (including contact time and 
preparation outside of sessions) was 185 (126–263) min. Fidelity 
of intervention delivery median (IQR) scores were 97.2% (92.3–
100.0), 92.6% (87.0–98.1) and 94.4% (91.7–97.2) at the first 
intervention visits, reviews and phase reviews, respectively (4)).
For the primary outcome, over 12 months, there were 526 
pulmonary exacerbations in the usual care arm (adjusted rate 
1.77/year, n=303) compared with 482 in the intervention 
arm (1.63/year, n=304). Incidence rate ratios (95% CI) of the 
primary analysis (0.96 (0.83 to 1.12); p=0.64), sensitivity anal-
yses (online supplemental table 3) and subgroup analyses (online 
supplemental figure 1) indicated no significant between- arm 
difference in exacerbations.
Mean objectively measured effective adherence in weeks 3–52 
was 52.9% in the intervention arm versus 34.9% in the usual 
care arm, with an adjusted mean difference of 9.5 percentage 
points (95% CI 8.6 to 10.4). Figure 3 shows that adherence 
declined rapidly at a similar rate in both groups during the first 
3 weeks of the trial. The decline among usual care participants 
continued over the subsequent 12 weeks, then stayed at the level 
until the end of the trial. In the intervention group, adherence 
subsequently improved following delivery of the behaviour- 
change intervention from week 3 onwards (further details in 
online supplemental appendix D).
Over 12 months, percent predicted FEV1 declined by 1.4 
(from 58.3±22.6 to 56.9±23.0) among usual care and 0.1 (from 
60.7±23.5 to 60.6±24.2) among intervention participants. The 
adjusted mean differences (95% CI) in per cent predicted FEV1 
and BMI at 12 months were 1.4 (−0.2 to 3.0) and 0.3 kg/m2 (0.1 
to 0.6), respectively (table 3).
Of the eight CFQ- R subscales, seven showed no between- 
group difference, but there was lower perceived CF treatment 
burden (3.9 (1.2, 6.7) points) in the intervention arm. Of the 
other 11 patient- reported outcomes at 12 months (including two 
safety measures; table 3), six showed differences for intervention 
versus usual care (adjusted difference in means (95% CI)), with 
increases in beliefs about medication necessities (0.1 (0.0 to 0.2) 
on BMQ- Specific necessities), habit strength for using nebuliser 
(1.2 (0.5 to 1.8) on SRBAI), perceptions of treatment adherence 
(0.7 (0.2 to 1.2) on three- item scale) and patient activation (3.4 
(1.3 to 5.4) on PAM-13), and decreases in concerns about treat-
ment (0.2 (0.1, 0.2) on BMQ- Specific concerns) and perceived 
effort of nebuliser treatments (0.3 (0.1 to 0.5) for one item). 
Other outcomes, including the safety measures of depression 
(−0.1 points (−0.8 to 0.7) on PHQ-8) and anxiety (0.3 points 
(−0.4 to 1.0) on GAD-7), showed no between- group difference.
No intervention- related serious adverse events were reported 
(online supplemental table 4). Sixty- four serious adverse events 
(21 in expected categories due to disease or treatment) in 43 
usual care participants were recorded and 71 (28 expected) in 
56 intervention participants.
DISCUSSION
In this randomised, usual care- controlled trial, we investigated 
the effectiveness of a self- management intervention designed 
to reduce pulmonary exacerbation rates among adults with CF, 
by supporting their adherence to inhaled mucoactive agents 
and antibiotics. Over 12 months, a significant difference in 
pulmonary exacerbations or FEV1 was not detected. However, 
compared with usual care, the intervention achieved higher 
objectively measured effective adherence, higher BMI and lower 
perceived CF treatment burden.
It is possible that the primary outcome was not achieved due 
to insufficient between- group difference in adherence. It is also 
possible that using exacerbation as an endpoint was problem-
atic. Exacerbation is a robust, sensitive outcome for blinded 
efficacy drug trials,21 but an unblinded, pragmatic evaluation of 
self- management support presents challenges to its use. There 
is a discretionary element to the use of intravenous antibiotics 
as rescue therapy; previous studies suggest only around 50% of 
events meeting 3/4 Rabin exacerbation criteria or acute 10% 
decline in FEV1 receive additional antibiotics.
26 Increasing a 
person’s adherence to treatment may improve their acceptance 
of intravenous antibiotics,27 and more intense monitoring can 
detect more exacerbations.28 It is possible that increased clini-
cian contact time in the intervention group created differential 
surveillance that biased the exacerbation rate towards unity 
(ascertainment bias). In UK practice, intravenous antibiotics 
will always be started by the CF care team, whereas oral anti-
biotics can be started in the community and may be much more 
susceptible to differential surveillance. To avoid this bias, oral 
courses were not collected. As a consequence, it is possible that 
improvement in milder exacerbations may have been missed. 
Adding a standardised criteria, for example, the Fuchs criteria, as 
part of the definition allowed exacerbation measurement across 
different centres to be comparable. However, recent work has 
suggested that this may result in reduced sensitivity.29
The graph for objectively measured effective adherence 
(figure 3) has several features that merit discussion (further 
Figure 3 Medication adherence over 12 months, by randomised 
group (usual care n=295; intervention n=293). *Objectively measured 
effective adherence (sum of doses taken/sum of doses prescribed) was 
calculated on a weekly basis, with adjustments made against what 
may be considered an ideal treatment for effectiveness, as based on 
the following rules: all participants should receive at least a muco- 
active agent; and all participants with chronic Pseudomonas should 
receive at least both a mucoactive agent and an antibiotic. Adherence 
data were aggregated and plotted weekly for the purpose of detecting 
whether adherence is actually changing to smooth out daily fluctuations 
that may just be noise, for example, due to weekday versus weekend 
differences in adherence.40








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































details in appendix D). The pragmatic trial design of providing 
data- logging nebulisers and revealing trial allocation to partici-
pants on day 1, then measuring baseline adherence in the first 
2 weeks of the trial creates complexity. The baseline between- 
group difference in objectively measured effective adherence 
was 8.6% in favour of the intervention group (54.1%±33.0% 
vs 45.5±34.1%), with the intervention group being older yet 
having higher FEV1 and lower IV days in the 12 months prior 
to study entry. Over the 49 weeks of the intervention, there 
was a between- group difference in objectively measured effec-
tive adherence of 18.0% in favour of the intervention group 
(52.9%±31.4% vs 34.9±31.7%), with an adjusted mean differ-
ence of 9.5% (95% CI 8.6% to 10.4%) taking into account the 
baseline adherence. Analysis comparing the adherence response 
stratified by baseline adherence (appendix D (figure D2)) shows 
that a significant between- group difference in adherence emerged 
at all levels of baseline adherence, emphasising that there was 
genuine divergence in adherence between the intervention and 
usual care independent of baseline adherence. It can be seen 
(figure 3) that in both groups there was an initial rapid decline 
in adherence. Among usual care participants not receiving any 
intervention, this decline continued over the next 12 weeks to 
around 35% and stayed at this level until the end of the trial. 
Real- world objective inhaled therapy monitoring has demon-
strated similar levels of adherence among adults with CF not 
receiving intervention.8 9 In the intervention group, the initial 
rate of decline was similar to usual care until the behavioural 
change intervention started from week 3 onwards and adherence 
subsequently improved. Given the rapid initial decline of both 
groups over the first 3 weeks of the study, it seems possible that 
the adherence at study entry was a short- term manifestation of 
device novelty30 and white coat adherence.31
Since people with low adherence may find adherence data 
threatening,32 it is important to note that the differential adher-
ence in the intervention arm was achieved without increasing 
anxiety. The intervention also achieved increase in necessity 
and reduction in concerns for treatment taking, consistent with 
literature highlighting that self- management of LTCs may be 
improved by addressing treatment beliefs.17 Policy makers who 
emphasise the importance of patient activation in LTCs33 can 
be reassured that the intervention significantly increased knowl-
edge, skills and confidence (patient activation). The intervention 
achieved clinically important improvements in perceived treat-
ment burden,34 which was identified as the number one research 
priority by the CF community.12 That total nebuliser use should 
increase while the perceived burden and effort of nebuliser treat-
ment decrease may relate to a moderating role for habit.18 19 
Literature in LTCs emphasises that sustained adherence is gener-
ally more strongly associated with habit than reflective motiva-
tion, which is more effortful.35
In considering the effective components of the intervention, 
data feedback is an obvious candidate. However, participants 
consulted data infrequently outside of supervised sessions. A 
qualitative analysis undertaken as part of the pilot work reported 
the value of the range of behaviour change techniques used in 
the intervention as well as the importance of building a relation-
ship with the interventionist.36 It is unlikely that unsupported 
feedback alone is sufficient to explain the reduced treatment 
burden, the improved necessity and concerns for treatment or 
the increased habit strength.
A strength of the trial is the automatic capture of objective 
adherence with data- logging nebulisers that record every dose 
taken. Online supplemental table 2 demonstrates similar levels 
of week- by- week data completeness for both groups. Robust 
adherence data allowed us to demonstrate a sustained adher-
ence difference for 12 months, which is the first for inhaled 
medications in any LTC. Sustained objectively measured adher-
ence benefits for behavioural interventions in other LTCs are 
limited to two studies, both for oral medications among older 
adults in the hypertension and post- transplantation settings.37 38 
CFHealthHub as a multi- component self- management interven-
tion has now been established as a digital learning health system 
(ISRCTN14464661) in >50% of UK adult CF centres. Limita-
tions of the trial include the delivery of both behavioural change 
and research procedures by interventionists, a period of server 
downtime that affected intervention delivery, the fact that the 
trial powered for exacerbation was not designed to detect the 
observed point estimate in FEV1 and the recruitment of a conve-
nience sample whereby a third of the participants had objectively 
measured effective adherence levels >75%. The vulnerability 
of adherence studies to differential inclusion of more engaged 
patients is likely to reduce both the impact of the adherence 
intervention on studied behaviour and reduce the impact on 
health outcomes.39 This may mean that the positive behavioural 
findings observed in this study are particularly noteworthy. The 
direction of bias and implications of these limitations are further 
discussed in appendix E.
In this randomised controlled trial, an intervention for adults 
with CF that combines measurement of objective adherence to 
prescribed medication using data- logging nebulisers, a digital 
platform and manualised behavioural- change sessions delivered 
by trained clinical interventionists did not significantly affect 
pulmonary exacerbations and FEV1 but did result in higher 
objectively measured effective adherence, higher BMI and 
lower perceived CF treatment burden versus usual care, without 
increasing anxiety. This is the first iteration of a self- management 
intervention that may have the potential to be improved by 
continual iteration in a digital learning health system. Analogous 
to the overwhelming success in the CF drug pipeline of building 
on early signals with ongoing developments and trials, we plan 
to continue iterating and evaluating the CFHealthHub- based 
intervention by building on signals we have observed to further 
improve the intervention. Given that adherence is low in LTCs 
and that prescribed medications only work if taken appropri-
ately, focusing on further evaluation of adherence interventions 
is important.
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Table S1 Cluster sample size calculations for comparison of continuous data – two independent groups 
 
 
*Power calculations demonstrated greater efficiency of pulmonary exacerbations versus FEV1, thereby influencing the choice of pulmonary exacerbations 
as the primary outcome. 
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†Randomisation in the trial was on an individual rather than cluster basis because our power calculation indicated a requirement for 1,400 adults across  
20 centres for cluster randomisation, which would not be feasible. Although contamination is a risk with individual randomisation, this can often be 
overcome by increasing the sample size. In most cases, individual randomisation accounting for contamination requires a smaller sample size than cluster 
randomisation.1 
FEV1, forced expiratory volume in one second; RCT, randomised controlled trial (c, cluster; i, individual); SD, standard deviation. 
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Table S2 Objectively-measured effective adherence weekly summaries 
(complete case), by randomised treatment group 
Week Usual care Intervention 
 
N Mean (SD) N Mean (SD) 
1 289 48.0 (35.0) 290 57.0 (34.2) 
2 295 43.7 (35.1) 293 51.4 (34.6) 
3 298 39.9 (34.8) 295 49.7 (34.3) 
4 297 39.7 (35.4) 297 50.3 (35.1) 
5 293 40.5 (34.9) 298 51.4 (34.9) 
6 291 38.6 (34.5) 299 54.7 (34.7) 
7 291 38.2 (35.1) 298 54.4 (35.2) 
8 292 38.1 (35.9) 298 53.8 (36.1) 
9 292 37.4 (35.3) 297 54.3 (35.0) 
10 291 36.6 (34.7) 297 54.0 (35.9) 
11 290 36.4 (34.8) 297 54.9 (35.6) 
12 290 38.0 (34.9) 297 56.9 (35.7) 
13 290 38.4 (35.6) 296 55.6 (36.4) 
14 290 37.0 (35.2) 294 55.1 (36.9) 
15 289 36.0 (34.9) 293 56.1 (36.8) 
16 286 35.8 (34.8) 293 55.1 (36.3) 
17 286 36.3 (34.4) 293 55.2 (35.7) 
18 285 34.9 (34.6) 293 53.9 (35.6) 
19 285 35.5 (34.7) 293 55.2 (35.1) 
20 285 34.6 (35.1) 293 54.5 (36.0) 
21 283 34.7 (36.5) 292 54.2 (37.1) 
22 283 35.7 (36.6) 292 54.1 (36.3) 
23 283 34.2 (35.7) 291 55.0 (36.4) 
24 282 34.5 (34.8) 290 55.3 (35.8) 
25 282 34.7 (34.0) 290 53.2 (35.9) 
26 281 34.6 (33.8) 290 54.3 (36.0) 
27 281 34.4 (34.5) 288 53.9 (36.6) 
28 279 35.2 (35.9) 288 54.2 (35.7) 
29 280 36.0 (35.8) 287 53.1 (36.0) 
30 276 36.0 (35.9) 287 54.1 (36.4) 
31 275 35.4 (35.5) 285 56.3 (36.5) 
32 274 33.7 (34.0) 285 54.1 (36.7) 
33 274 33.3 (34.5) 284 53.0 (37.2) 
34 274 33.0 (33.5) 283 52.3 (36.8) 
35 273 33.9 (34.5) 282 52.3 (36.7) 
36 273 35.6 (35.1) 281 52.5 (36.4) 
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37 272 35.6 (34.3) 279 53.3 (35.6) 
38 272 35.5 (35.1) 279 52.6 (36.1) 
39 272 34.2 (34.8) 279 51.6 (37.2) 
40 272 35.5 (35.4) 276 50.6 (37.4) 
41 272 33.4 (34.2) 275 52.9 (35.9) 
42 272 33.8 (33.9) 274 53.8 (36.2) 
43 272 32.7 (35.1) 274 53.1 (36.4) 
44 271 32.0 (34.4) 272 52.0 (37.3) 
45 271 32.7 (34.9) 272 52.6 (36.6) 
46 269 33.3 (34.8) 272 52.0 (36.4) 
47 269 32.9 (34.5) 271 50.6 (37.4) 
48 269 33.9 (35.7) 271 49.3 (37.1) 
49 269 34.7 (35.6) 269 50.8 (36.6) 
50 268 32.8 (35.8) 269 52.0 (36.0) 
51 267 33.1 (35.3) 269 52.7 (35.9) 
52 266 33.2 (35.0) 268 51.4 (36.1) 
SD, standard deviation. 
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Table S3. Primary outcome sensitivity analyses over 12 months, by randomised treatment group 
Sensitivity 
analysis* 
Usual care Intervention Incidence rate ratio 
(95% CI) 
P 




















303 558 297.2 1.88 304 504 294.9 1.71 0.95  
(0.82, 1.10) 
0.511 









Main – adjusted for stratification factors (centre and past-year IV days) 
Main – unadjusted for any covariates except duration of post-consent follow-up 
All exacerbations – main model including additional exacerbations meeting Fuchs’ criteria but not treated with parenteral antibiotics 
MICE – missing count data imputed (where missingness not due to death) using randomization group, site, previous year’s IV days, age, gender, 
FEV1 % predicted, Pseudomonas status, and exacerbation count 
Best case imputation – missing intervention arm follow-up time imputed (where missingness not due to death) assuming no further exacerbations 
Recurrent event survival – extension of proportional hazards time-to-event model allowing for repeat events (exacerbations) with no assumption of 
constant event rate 
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*Recurrent event survival was also calculated: hazard ratio 0.95 (95% CI 0.80, 1.13; p=0.567). 
†The difference between ‘all exacerbations’ and ‘main – unadjusted’ is the number of IV antibiotic courses that were offered by clinicians but declined by 
participants. The IV-declined rate was 32/558 (5.7%) for the usual care arm and 22/504 (4.4%) for the intervention arm. These values are far lower than 
the IV-declined rate observed in the general CF population of around 20%,1 which provides evidence that the recruited participants may not be 
representative of the general CF population. 
BMI, body mass index; CF, cystic fibrosis; CI, confidence interval; EQ-5D-5L, EuroQol 5-dimension and 5-level;  
FEV1, forced expiratory volume in one second; IV, intravenous; MICE, multiple imputation using chained equations. 
 
Reference 
1. Hoo ZH, Bramley NR, Curley R, et al. Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: a prospective 
observational study. Respir Med 2019;154:109–15. 
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Figure S1 Primary outcome subgroup analysis according to baseline objectively-measured 





Statistical significance was not observed in any of the subgroups by baseline objectively-
measured effective adherence. “Pulmonary exacerbation” was defined as the administration 
of intravenous (IV) antibiotics for any of the 12 Fuchs’ symptoms/signs. As discussed in the 
main manuscript, there is a discretionary element to the use of IV antibiotics as rescue 
therapy to treat exacerbations. Increasing a person’s adherence to inhaled therapies may 
also improve their engagement with other treatments, including improving their acceptance 
of IV rescue antibiotics. It is possible that the exacerbation rate appeared to have somewhat 
increased in those with baseline adherence 26–50% because this is the subgroup with 
greatest improvement in adherence, potentially leading to the greatest impact from 
ascertainment bias (see appendix D [figure D2] for the subgroup analysis of adherence). It 
should be noted that interactions between exacerbations and adherence are complex, 
including for example the impact of engagement on IV acceptance, such that interpretation 
should be made with caution.
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Number of AE, overall – n (% of all AE) 301 (46.9) 341 (53.1) 
Number of participants experiencing ≥1 AE 
– n (% of participants in treatment arm) 
125 (41.3) 139 (45.6) 
Number of AE, by category  
– n (% of AE in treatment arm) 
  
 Expected* 242 (80.4) 263 (77.1) 
 Other 58 (19.3) 73 (21.4) 
Serious AE*†   
Number of serious AE, overall  
– n (% of all serious AE) 
64 (47.4) 71 (52.6) 
Number of participants experiencing ≥1 serious AE 
– n (% of participants in treatment arm) 
43 (14.2) 56 (18.4) 
Number of serious AE, by category  
– n (% of serious AE in treatment arm) 
  
 Expected* 21 (32.8) 28 (39.4) 
 Other 41 (64.1) 42 (59.2) 
 Unknown 2 (3.1) 1 (1.4) 
*Certain AE common to CF and associated medications were categorised as expected. Examples 
of expected AE include acute FEV1 drop >15% after first dose of medication, increased productive 
cough and nasal congestion. The full list of expected AE is provided in section 12.3.3 of the 
protocol (available as supplementary material). 
†There were no serious AE deemed related to the intervention (non-serious AE were not assessed 
for relatedness).  
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APPENDIX A Description of the CFHealthHub intervention 
Aim 
The CFHealthHub intervention aims to support adults with cystic fibrosis (CF) to increase and 
maintain their adherence to prescribed nebulised medication in order to reduce exacerbations 
and improve or prevent decline in lung function. 
 
Rationale  
The CFHealthHub intervention is underpinned by the Capability Opportunity Motivation-
Behaviour (COM-B) model.1 It has been developed using the Behaviour Change Wheel 
approach alongside a person-based approach to intervention development. This process is 
described in detail elsewhere2 but broadly consisted of the following stages: 
• Identification of barriers and facilitators for nebuliser adherence using the Theoretical 
Domains Framework 
• Identification of appropriate intervention functions and behaviour change techniques 
to address barriers identified 
• Iterative development of the CFHealthHub intervention with patients, using feedback 
from interviews and 'think aloud' to refine the intervention 
• Creation of an intervention manual and training programme for interventionists 
• Pilot and feasibility trial including a process evaluation which was used to further refine 
the intervention, manual and training process 
 
Conceptual framework and theory 
The conceptual framework that describes the intervention is provided in figure A1. Consistent 
with the COM-B model, the framework considers issues of capability, opportunity and 
motivation, all of which must be present in order for repetition of the behaviour (i.e. medication 
adherence) to occur. Initially we anticipate that repetition will require effortful self-regulation, 
but with repetition and strategies to promote habit formation we aim for the behaviour to 
become more automatic. 
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Figure A1 Sustained behaviour conceptual framework. 
 
 
The intervention addresses a range of different barriers and is tailored to meet the specific 
needs of the person. The intervention draws on key theories in order to address different parts 
of the proposed process: Social Cognitive Theory,3 Control Theory,4 and Habit Theory,5 as 
follows: 
• Social Cognitive Theory (SCT)3 proposes that behaviour is influenced by two core 
constructs: i) perceived self-efficacy, i.e. an individual's beliefs in their capability to 
adhere to treatment; and ii) outcome expectancies, i.e. an individual's beliefs about the 
likely consequences of their actions. Self-efficacy can be enhanced through: i) mastery; 
ii) vicarious experiences, where a role model, similar to the individual successfully 
achieves behavioural change in a similar situation; or iii) verbal persuasion. Outcome 
expectancies include beliefs about the positive and negative and short- and long-term 
consequences of adherence, and in this context include perceived necessities and 
concerns.6 According to SCT, outcome expectancies may result in intentions to change 
one’s behaviour. Self-efficacy then influences the translation of that intention into 
action through the pursuit of goals. 
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• Control Theory4 explains the processes of self-regulation. When a behavioural 
standard or goal has been set, an individual directs their attention through monitoring 
behaviour to the discrepancy between their current behaviour and their goal. They then 
use this feedback to regulate their behaviour to meet their goal through action control. 
This in the context of adherence, once an adherence goal is set, self-monitoring of 
treatment-taking provides the feedback to prompt action to enable self-regulation of 
behaviour. 
• A habit is where a behaviour is prompted automatically by a situational cue. Habits are 
created due to the repetition of a behaviour in a specific context7 which, over time 
results in a learned cue-behaviour association.8 In the context of adherence, the 
repeated taking of treatment in a specific context or in the presence of a specific cue 
should over time result in the formation of a habit. Habits are particularly advantageous 
because theory predicts that, once formed, they do not rely on motivational processes 
and therefore should persist even if motivation wanes.9 They may therefore play a 
particularly important role in the promotion of long-term maintenance of behaviour,10 in 
this case adherence which is a key aim of the programme. 
 
Materials 
The CFHealthHub intervention includes a range of materials as follows: 
1. eFlow Technology nebulisers with eTrack data-logging Controllers (PARI Pharma 
GmbH, Starnberg, Germany) 
2. 2net Hub (Capsule Technologies, San Diego, USA) 
3. Research procedures manual 
4. CFHealthHub web platform 
5. CFHealthHub app (available for Apple and Android devices) 
6. COM-B Beliefs about Medicines Questionnaire (COM-BMQ) screening tool 
7. CFHealthHub Participant manual 
8. CFHealthHub Interventionist manual including worksheets for intervention delivery 
9. Training slides, and online resources (via Blackboard virtual learning environment 
[VLE]) for interventionist training 
10. Fidelity scoring sheets 
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Intervention providers 
Intervention providers were recruited from each site. The majority of sites recruited individuals 
who were already members of the multi-disciplinary teams working in CF at that site. Other 
sites recruited from other parts of the hospital or recruited externally.  
Thus, interventionists had a range of backgrounds including: 
• Physiotherapists working in CF or other respiratory conditions 






Interventionist training, assessment and support 
Interventionists received training in how to deliver the intervention in a variety of ways: 
1. Training in use of equipment 
Interventionists received training in how to use the eTrack nebuliser and 2net Hub, how to pair 
the devices, and how to register a new participant onto the CFHealthHub platform and PARI 
Track system, as part of their research procedures training. This was delivered face-to-face 
by the study manager and PARI, and supported with a research procedures manual and ad-
hoc telephone support throughout the trial. 
2. Training in delivery of CFHealthHub intervention 
Interventionists received training in how to use the CFHealthHub web platform and how the 
deliver the CFHealthHub intervention. Training was delivered over a 2-day face-to-face 
training session, followed by a schedule of online training to be completed over the equivalent 
of 4 days hosted by the Blackboard VLE. Training consisted of presentations with exercises 
in small groups or pairs, supported use of CFHealthHub, role play delivery of the intervention 
and discussion. A training version of the CFHealthHub platform was provided for use during 
training that included dummy data. Interventionists were paired to form buddies for support 
and additional role play during the online part of the training. 
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3. Competency assessment 
Interventionists undertook two competency assessments during the training period:  
i. Theory test, which assessed understanding of the content of the CFHealthHub web 
platform content and data. This test was delivered through an online survey on the 
VLE and consisted of multiple choice and short answer questions. The answers were 
marked according to a pre-determined marking schedule. Interventionists passed if 
they received a mark of ≥80%. Individual feedback was provided on the answers given; 
where the first test was failed, additional tutorial support was provided and the test 
retaken until passed.  
ii. Practical test, which assessed delivery of the first intervention visit of the CFHealthHub 
intervention. This was assessed through an audio-recorded role play. The part of the 
participant was played by a member of the study team and the interventionist role-
played their part. The intervention delivery was assessed using a competency 
assessment sheet which consisted of sections on preparation, delivery of intervention 
components, and the quality of delivery. Two members of the training team looked at 
the completed worksheet for the session and listened to the accompanying audio-
recording. They then discussed the marks and agreed marks where there were any 
differences. Agreed marks for each section were averaged and the pass mark was 
90%. Interventionists received individual feedback on their performance and tutorial 
support where they had failed. The test was retaken until passed.  
Competencies to deliver a review visit and a phase review visit were assessed by listening to 
the first audio-recorded visit of that kind for each interventionist. Two members of the training 
team looked at the completed worksheet for the session and listened to the accompanying 
audio-recording. They then discussed and agreed marks. Agreed marks for each section were 
averaged and the pass mark was 90%. Interventionists received individual feedback on their 
performance and tutorial support where they had failed. The next audio-recorded visit of that 
kind was assessed where the assessment was failed. 
4. Ongoing support 
Ongoing support for interventionists was delivered via a weekly teleconference, email and 
telephone support with the training team, technical support via telephone and email. The 
weekly teleconference provided a space where interventionists could discuss problems, 
successes and case studies (anonymised), to aid group learning. Individuals could also 
access members of the team individually and individual interventionists were targeted with 
support where they had failed their earlier competency assessment or where there were any 
problems identified.  
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Intervention schedule of delivery 
The intervention schedule of delivery is described in figure A2. The content of each kind of 
intervention session is described below. Within this schedule there are a number of different 
paths that were determined during delivery. 
Consent visit and set-up 
All participants receive their eTrack nebuliser and 2net Hub at the consent visit. They also 
complete the COM-BMQ screening tool at this visit. An account is created on CFHealthHub 
into which is added the current prescription data for the participant and the data from the COM-
BMQ screening tool. The consent visit takes place ≥4 weeks prior to the first intervention visit. 
During this time adherence data is transmitted automatically from the eTrack nebuliser via the 
2net Hub, which is plugged into their home, to the CFHealthHub platform. Figure A3 shows 
this process. 
Intervention sessions received by all participants 
All participants receive their first intervention visit ≥4 weeks following consent (so that the 
consultation is based on ≥4 weeks’ worth of objectively-measured adherence data). This visit 
is always done face-to-face although can be in a variety of locations, including hospital (in-
patient), clinic or home. All participants then receive an intermediate review phone call one 
week later. Subsequent visits depend on their objectively-measured effective adherence level. 
Participants with an adherence level of ≥80% follow the 'Very high adherence' pathway while 
those with adherence level of <80% follow the normal pathway. 
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Figure A2 Schedule of intervention delivery. IV, intravenous antibiotics. 
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Figure A3 Data transfer process.  
 
 
Normal pathway (adherence less than 80%) 
Participants on this pathway have intervention sessions over a 12-week period. In addition to 
the first intervention session (at week 0) and an intermediate review (at week 1), they receive 
a review session at week 4, an intermediate review at week 6, a second review session at 
weeks 8 or 9, and a phase review at week 12. This pattern of delivery constitutes a phase. 
They then receive a phase review session every 12 weeks, or every 6 weeks if their 
objectively-measured effective adherence level is <25%. 
Very high adherence pathway (adherence 80% or more) 
Participants on this pathway have intervention sessions over a 4-week period. In addition to 
the first intervention session (at week 0) and an intermediate review (at week 1) they receive 
a phase review at week 4. They then receive a phase review session every 12 weeks. 
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Triggers 
In addition to the pathways outlined above there are a number of criteria which, if met, trigger 
a new phase of intervention delivery. These are:  
i. Participant requested support. This can be a request for additional support at a phase 
review in which case an additional intervention delivery period is triggered without a 
break, or at any other time. 
ii. Additional periods of delivery are offered to participants if one or both of the following 
triggers occurs following the first phase review. 
iii. A drop of ≥20% in objectively-measured effective adherence since the phase review. 
iv. An exacerbation requiring intravenous treatment. 
In any of these situations, participants are contacted, and additional support is offered. If 
participants agree then the triggered pathway commences with a review session at week 0, 
an intermediate review 1 week later, a review visit 4 weeks later, and a phase review 6 weeks 
later. Participants then revert back to phase reviews every 12 weeks intervals (or every 6 
weeks for those with an objectively-measured effective adherence level of <25%). 
 
Access to CFHealthHub 
Participants have an individual login providing access to the CFHealthHub platform throughout 
the intervention. It can be accessed on a laptop or via an app available for Apple or Android 
devices. 
Participants are encouraged to access the site regularly and are provided with a participant 
guide with instructions on how to access and information about what to find where. 
 
Intervention modules 
The CFHealthHub contains a number of distinct modules each of which focuses on a different 
aspect using a range of specific behaviour change techniques (described using the definitions 
in the behaviour change taxonomy)11 and modes of delivery. Table A1 describes these 
techniques, and which aspects of the intervention were delivered using the CFHealthHub 
platform and which were delivered by the interventionist. 
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Table A1 Modules, behaviour change techniques and mode of delivery for the 
CFHealthHub intervention 
Module Behaviour change 
techniques11 
Mode of delivery 















• Information about CF, the need for treatment, how 
each treatment works and the importance of 
adherence 
• Information presented in a variety of ways though 
written text, patient stories, 'talking heads' and 
animation videos, with links to external content 
including Cochrane reviews 
• Range of different credible information sources 
including people CF, clinicians, links to scientific 
papers 
Interventionist: 
• Interventionist introducing and highlighting relevant 
content on CFHealthHub 











• Charts and tables of objective adherence data 
presented within CFHealthHub 
Interventionist 










• 'Talking heads' videos of coping stories within 
CFHealthHub 
Interventionist 
• Interventionist encouraging focus on periods of 
higher adherence on charts 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax

















• Indication of goal line on charts of adherence  
• Visual indication of goal met on CFHealthHub  
• (Optional) weekly push notifications indicating 
whether goal was met 
• (Optional) reward messages sent when goal met 
Interventionist 
• Discussion and agreement of goals with 
interventionist 
• Review of goals  
• Suggested steady increase in goal as improvements 
are made 








• Action planning tool and storage within 
CFHealthHub 
Interventionist 
• Help to focus on identifying consistent cues and 
linking to behaviour (habit formation) 
• Discussion and identification of appropriate cues - 










Instruction on how 







• Solution bank within CFHealthHub (including advice 
to problem solve, restructure the physical 
environment, engage social support) 
• Coping planning, Day planner and Party planner 
tools and storage within CFHealthHub  
• Videos demonstrating correct use of nebulisers 
within CFHealthHub 
Interventionist 
• Tailored problem solving guided by interventionist 
• Support to create Day plans/Party plans where 
appropriate 
• Support to construct if-then coping plans including 
identifying self-talk where appropriate 
CF, cystic fibrosis 
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Tailoring and personalisation 
The CFHealthHub intervention is not one-size-fits-all and is designed to be tailored and 
personalised so that it can best meet the needs of a wide range of participants. While the 
entire content of the CFHealthHub website is available for participants to browse, tailored 
aspects are emphasised or added into a specific personal 'favourites' area called 'My Toolkit'. 
Table A2 describes the ways in which the intervention is tailored. 
 
Table A2 Tailoring of the CFHealthHub intervention 
Tailored component How non-tailored 
components are 
accessed 
How version is determined 
Contents of 'My treatment' 
and 'Problem-solving' focus 
on information relevant to 
current prescription drugs 
All generic information is 
available to all 
participants to browse 
Information on 
treatments not currently 
prescribed are available 
but minimised 
Prescription is entered into CFHealthHub 
at consent and altered whenever there is 
a prescription change 
CFHealthHub automatically tailors 
content based on this information 
Modules of 'My treatment' 
are selected and placed 
into 'My Toolkit' based on 
the scores on the COM-
BMQ questionnaire 
Participants can browse 
all modules of 'My 
treatment' 
Participants responses to the COM-BMQ 
questionnaire are entered into 
CFHealthHub at consent. CFHealthHub 
recommends the most relevant modules 
based on a scoring algorithm 
If CFHealthHub recommends >3 modules 
then interventionists select 3 based on 
the scores and their judgement based on 
conversations with the participant 
Modules can be changed throughout the 
intervention and these are recorded via 
CFHealthHub 
Modules of 'Problem-
solving' are selected and 
placed into 'My Toolkit' 
based on the barriers 
identified in consultations 
with the interventionist 
Participants can browse 
all modules of 'Problem-
solving' 
Interventionists can select modules of 
problem-solving content based on the 
barriers identified in consultations 
Modules can be changed throughout the 
intervention and these are recorded via 
CFHealthHub 
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'Talking heads' videos are 
selected to match key 
participant characteristics 
and placed into 'My Toolkit'. 
This is optional 
Participants can browse 
the entire 'talking heads' 
video library 
Interventionists can select relevant 
videos that match key characteristics of 
the participant (e.g. age, gender, 
occupation, life role, problems 
experienced) 
Videos can be changed throughout the 
intervention and these are recorded via 
CFHealthHub 
Goal-setting and review 
and Treatment planning are 
only utilised for participants 
who are motivated (want to) 
take more treatment 
Participants with very low 
motivation do not receive 
these parts of the 
intervention. Instead they 
spend more time focusing 
on the content of 'My 
treatment' and relationship 
building with the 
interventionist 
Participants can choose 
to set goals and make 
plans at any point in a 
consultation or by 
contacting the 
interventionist 
Very low motivation is determined by a 
combination of a low motivation score on 
the COM-BMQ motivation item and 
discussion with the participant in a 
consultation 
The identification of very low motivation is 
recorded where this applies 
COM-BMQ, COM-B Beliefs about Medicines Questionnaire. 
 
 
A number of features of CFHealthHub are individually personalised for each participant. These 
are described in table A3. 
 
Table A3 Personalisation of the CFHealthHub intervention 
Personalised component How personalisation is achieved 
Graphs and charts show 
personal data 
Participants eTrack nebuliser collects and send adherence data 
to CFHealthHub via the 2net Hub for display 
Target line on graph Participants determine their adherence goal in consultation with 
the interventionist. This is displayed on their charts 
Plans Participants make individual plans based on discussions with the 
interventionist. These are made using the tools within 
CFHealthHub and recorded in 'My Toolkit'. New plans can be 
added and CFHealthHub records all plans for each participant 
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Home page  Participants can select an image to display on their home page 
from a default selection, or can upload their own image 
Notifications Participants can optionally choose to receive personalised 
notifications via the CFHealthHub app. These send a message to 
let the participant if they have met their goal in the previous week 
or an encouraging messaging to keep going if they did not 
Reminders Participants can optionally choose to receive reminders via the 
CFHealthHub app. These send a reminder message if the 
participant has not accessed their CFHealthHub account for a 
period of 2 weeks 
Reward messages Participants can optionally choose to receive reward messages 
via the CFHealthHub app. These send a reward message if the 
participant has met their goal in the last week, 2 weeks or month 
 
 
Types of intervention visit 
Broadly, the intervention visits all have the same aim, which is to enable participants to look 
at their data, reflect on why adherence is important, set goals to increase their adherence and 
make plans as to how they will achieve these, and problem-solve any barriers that are likely 
to get in the way. However, the intervention visit types do differ somewhat in their set-up, focus 
and how in-depth they are, as follows. Detailed information about the structure of the delivery 
for each type of session is provided in the intervention manual and the relevant worksheets. 
First Intervention visit 
This session always happens face-to-face, although this can be in a hospital/clinic setting or 
at home. It lasts between 40 and 60 minutes. It is the first time that the participant accesses 
the CFHealthHub platform and sees their data. Interventionists must prepare for this session 
by entering the data from the COM-BMQ screening tool and checking that data are coming 
through to CFHealthHub from the nebuliser.  
The key things that happen in this session are: 
• Participant receives their log-in details and accesses CFHealthHub 
• Participant (optionally) downloads the CFHealthHub app onto their smartphone 
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• Modules covered for all: 
o My treatment 
o Self-monitoring 
o Confidence building 
• Modules covered for those who want to increase their treatment adherence (sufficiently 
motivated) 
o Goal setting  




The intermediate review is a short session that is designed to trouble-shoot 'quick' and easy 
to solve problems (e.g. an action plan that isn't working). It is normally delivered by telephone 
and lasts 5 to 15 minutes. The review is less structured than other visits.  
Ad-hoc review 
This follows the same structure as the intermediate review but is delivered where there is 
unplanned face-to-face contact with a participant (e.g. in clinic). 
Review visit 
This session normally last 30 to 45 minutes and can be delivered face-to-face or by telephone. 
The session focuses on the data and what has happened in terms of adherence since the last 
visit. The precise focus will vary depending on the individual participant, e.g. a session with a 
participant who has met their goal would have a different focus to one with a participant who 
has not met their goal (or did not set one).  
Broadly thought, the session covers the following modules: 
• My treatment 
• Self-monitoring 
• Confidence building 
• Goal setting and review  
• Treatment plan 
• Problem-solving 
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Phase review 
The focus of this appointment is to facilitate reflection on progress since the intervention (or 
the current phase of delivery) began and to consider whether continued support is required or 
whether the participant wishes to manage their adherence independently. Ideally this should 
be delivered face-to-face but can be delivered by telephone. It normally lasts 20 to 30 minutes.  
It covers the following modules: 
• My treatment 
• Self-monitoring 
• Confidence building 
• Problem-solving 
 
Fidelity of intervention delivery 
Fidelity of delivery was assessed throughout the delivery of the intervention to ensure that 
interventionists continued to deliver the intervention as specified in the manual and training 
(assessment of drift). Two reviewers independently assessed a purposive sample of audio-
recordings and worksheets associated with the delivery of intervention sessions with 
participants (first intervention session, review and phase review) using a scoring sheet that 
was developed and piloted during the feasibility trial.  
Sessions were selected to represent a range of different sites, types of sessions with particular 
focus on interventionists who: 
• Had initially failed any of their certification assessments  
• Had high withdrawal rates (more than two participants withdrawn from the 
interventionist contact)  
• Had submitted <80% audio-recorded sessions from those participants who provided 
consent for them to be recorded 
• Had completed a lower than expected number of intervention visits and/or had fewer 
than average action and coping plans recorded in CFHealthHub 
 
Metrics for fidelity of intervention delivery 
There were 32 interventionists and a total of 213 fidelity of delivery assessments conducted 
during the randomised controlled trial. 
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110 assessments were assessed to explore drift in fidelity over the duration of the trial and a 
pass mark threshold of 80% was set was drift assessments. Of all paired assessments during 
the randomised controlled trial there was 97.2% agreement when comparing pass/fail 
decisions at the 80% threshold (207 of 213 assessments in agreement).  
Intervention fidelity delivery scores are summarised by session type in table A4 and by site in 
table A5. Delivery of the intervention had very good fidelity (overall fidelity by site range 79–
97%) with only one site not achieving over the mean threshold (>80%) on drift assessments.  
 
Table A4 Intervention fidelity delivery score summaries by session type 
Session type Assessment* N Median Interquartile range 




































*Reasons for assessment, with multiple reasons possible: certification (97), reassessment after 
failed certification (36), high withdrawal rate (18), insufficient audio-recorded sessions (37), fewer 
than expected intervention visits or action/coping plans created (82), random to ensure total 
assessment sample ≥20% of all interventionist visits (9). 
 
Table A5. Overall intervention fidelity scores by site 




1 92.4 11 93.2 
2 93.2 12 92.4 
3 96.6 13 94.8 
4 89.9 14 94.9 
5 78.7 15 87.4 
6 94.0 16 92.8 
7 89.3 17 94.3 
8 86.6 18 94.7 
9 98.3 19 95.0 
10 90.5   
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APPENDIX B The choice of adherence measure 
In the trial, to reflect effective medication use, adherence was calculated as normative 
(effective) adherence using objective data from Weeks 3–52 as the outcome and Weeks 1&2 
as the “baseline”. Objectively-measured effective adherence was adopted as an outcome 
measure because it better reflects the effectiveness of medication use in comparison to simply 
calculating percent adherence according to an agreed regimen between adults with cystic 
fibrosis (CF) and their clinical team, as we have detailed elsewhere.1-3 The calculation of 
objectively-measured effective adherence involves numerator adjustment (capping daily 
maximum nebuliser use at 100%) and denominator adjustment (to define the minimum 
effective treatment regimen) according to a person’s Pseudomonas aeruginosa status, as 
described in section 9.2.1 of the statistical analysis plan (available as supplementary material). 
For example, a person with chronic Pseudomonas aeruginosa infection should be on at least 
a nebulised muco-active agent and an antibiotic (i.e. three daily doses). If a person with 
chronic Pseudomonas aeruginosa infection only agreed to use nebulised dornase alfa once 
daily, adherence levels in outcome calculation will use the denominator of three daily doses. 
If that person was on aztreonam thrice daily and hypertonic saline twice daily, no denominator 
adjustment will be carried out because denominator adjustment only applies for less than ideal 
regimen. In particular, the denominator adjustment is important because there is a wide 
variation in the prescription of inhaled therapies between different centres.4 By standardising 
the denominator given the person’s clinical characteristics in calculating objectively-measured 
effective adherence, it is ensured that an increase in percentage adherence is due to an 
increase in nebuliser use (i.e. increase in the numerator) rather than simply due to a reduction 
in agreed prescriptions (i.e. decrease in the denominator).  
It is important to distinguish the concept of standardisation for effectiveness used as an 
outcome measure from individualised feedback to participants. Objectively-measured 
effective adherence allows standardisation based on randomised controlled trial evidence of 
what treatment is likely to work. Individualised target setting between clinical teams and people 
with CF continued to be informed by both considerations of effective treatments and 
considerations of what the person feels they wish to aim for. On occasions within the trial, 
clinicians and participant may have agreed on regimens that exceed the minimum number of 
doses that would be considered effective given a participant’s characteristics. Since effective 
adherence denominator adjustments are intended simply to ensure minimum level of 
effectiveness, no adjustments were necessary in the case of these participants. That is to say 
the denominator adjustment was a strategic instrument to ensure minimal level of 
effectiveness is being reflected in the calculation of percent adherence. 
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Figure B1 Data display of CFHealthHub. 
 
 
CFHealthHub interventionists were trained to continue to record prescriptions that fulfil the 
minimum effective dose requirement. In the example of figure B1, the participant is a person 
with chronic Pseudomonas aeruginosa infection who aimed for three daily doses of aztreonam 
but muco-active agent was not part of their agreed treatment target. Data feedback within 
CFHealthHub captured individualised targets by displaying a target reflecting the treatment(s) 
that the participant chose to aim for. If they used all three daily doses of aztreonam, their 
effective adherence on the day would be 3/(3 + 1) = 75%. This personalised decision would 
appear as the target set on CFHealthHub in the form of the green line on the graph (at 75% 
adherence). When fewer than three daily doses were used, the daily adherence bar will be 
displayed in orange (for example on 23 November). When three daily doses were used, which 
met their individualised target though it did not achieve an effective adherence of 100%, the 
daily adherence bar will be displayed in green (for example on 08 November). Therefore, the 
data display of CFHealthHub feeds back the individualised target. In this example, the agreed 
prescribed regimen was still recorded as three daily doses of aztreonam and a daily dose of 
dornase alfa, though the participant was only aiming for three daily doses of aztreonam. By 
lowering the treatment target rather than reducing prescribed doses, any deviation from 
effective targets will still be visible on CFHealthHub. It is important to emphasise that this data 
The green bar indicates that the participant’s 
individualised target has been achieved on that 
particular day. The individualised target is NOT 
necessarily 100% 
The orange bar indicates that the 
participant’s individualised target has not 
been achieved on that particular day 
 
The green line indicates the target 
chosen by the participant  
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax
 doi: 10.1136/thoraxjnl-2021-217594–10.:10 2021;Thorax, et al. Wildman MJ
30 
display was produced in collaboration with people with CF and reflected their preference for 
representing individualised targets within the context of the evidence base around optimally 
effective treatments.  
The primary analysis of adherence for randomised clinical trial reporting was standardised 
using the concept of adherence to a regimen considered to be effective. Any deviation from 
the guidance to enter effective prescription into CFHealthHub or errors that were made based 
on a lack of awareness, for example of Pseudomonas aeruginosa status, were corrected for 
in the analysis which ensured that adherence at all sites and for all participants were being 
compared on an equal basis, i.e. effective adherence. That is to say the analysis of participant 
data for someone with chronic Pseudomonas aeruginosa infection only using inhaled antibiotic 
recognises it to be a regimen not considered to be maximally effective by international 
consensus.5-7 Thus denominator adjustment in this case would ensure that the adherence 
level analysed against the primary outcome of exacerbation would be not be 100%, but would 
be capped to a maximum of 75%, as in the example of figure B1. Without such standardisation, 
a person with more effective nebuliser use would not be identified in the calculation of percent 
adherence. Rigour around effectiveness is an important element in understanding the 
relationship between adherence and health outcomes. For example, without denominator 
adjustment, a person with chronic Pseudomonas aeruginosa infection using an average daily 
dose of one inhaled antibiotic and one dornase alfa but prescribed a total of three daily doses 
would have adherence of 67% yet a similar person using just a daily dose of dornase alfa but 
prescribed a total of one daily dose would have adherence of 100%. 
By using objectively-measured effective adherence as the method of calculating adherence, 
we can be confident that an increase in percent adherence reflects more effective medication 
use. It is important, given the use of effective adherence, to highlight that participants with 
chronic Pseudomonas aeruginosa infection were equally distributed between intervention and 
usual care. Yet usual care had slightly higher prescribed daily doses (mean 3.1 vs 2.9, see 
table 2 of main manuscript for breakdown of prescribed doses), meaning that the denominator 
adjustment would have reduced effective adherence among intervention participants to a 
greater extent compared to usual care. That is to say the use of objectively-measured effective 
adherence if anything, would bias against the intervention group.  
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Figure B2 Mean inhaled doses taken per week. 
 
Figure B3 Weekly mean objectively-measured effective adherence. 
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It is reassuring that as the intervention was delivered, a clear between-group divergence in 
the mean inhaled doses emerged (figure B2). That is to say the intervention group used more 
doses of nebulisers, which mirrors the divergence in objectively-measured effective 
adherence (figure B3). Therefore, the difference in calculated percent effective adherence was 
driven by the number of doses taken (numerator) among intervention participants rather than 
prescription (denominator) adjustments. The fact that the absolute number of doses between 
intervention and control diverges indicates that the use of objectively-measured effective 
adherence is capturing a difference in absolute treatment use between intervention and control.  
The percent objectively-measured adherence without any adjustments also mirrors the 
difference observed with objectively-measured effective adherence, as shown in table B1. 
 
Table B1 Objectively-measured adherence, by unadjusted and effective calculations 
 Usual care Intervention 
Baseline (weeks 1 & 2) 
Unadjusted adherence 
        Mean (SD) 
        Median (IQR) 
Effective adherence 
        Mean (SD) 
        Median (IQR) 
N = 295 
 
48.2 (34.4) 
50.0 (14.3, 81.0) 
 
45.5 (34.1) 
42.9 (10.7, 76.4) 
N = 293 
 
56.4 (32.4) 
61.3 (28.6, 85.7) 
 
54.1 (33.0) 
57.2 (25.0, 84.2) 
Weeks 3 to 26 
Unadjusted adherence 
        Mean (SD) 
        Median (IQR) 
Effective adherence 
        Mean (SD) 
        Median (IQR) 
N = 301 
 
38.0 (33.0) 
29.0 (6.5, 68.3) 
 
35.9 (32.2) 
25.9 (6.2, 61.6) 
N = 301 
 
56.3 (31.6) 
63.6 (31.4, 84.3) 
 
53.7 (31.7) 
58.7 (26.8, 81.4) 
Weeks 27 to 52 
Unadjusted adherence 
        Mean (SD) 
        Median (IQR) 
Effective adherence 
        Mean (SD) 
        Median (IQR) 
N = 282 
 
35.4 (32.7) 
27.6 (4.0, 64.6) 
 
33.2 (31.7) 
24.4 (3.5, 59.8) 
N = 288 
 
55.2 (32.6) 
64.0 (23.3, 83.0) 
 
51.9 (32.6) 
56.2 (22.5, 81.4) 
IQR, interquartile range; SD, standard deviation. 
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APPENDIX C Participant recruitment 
As is discussed in appendix D, “baseline adherence” of the participants may have been 
exaggerated by novelty effect and white coat adherence. Nonetheless, we also acknowledge 
that the study may have recruited a convenience sample that was more focused on adherence 
compared to the general cystic fibrosis (CF) population. The baseline median adherence of 
the participants was 52% whereas real world median adherence among adults with CF has 
been reported as closer to 35%.1,2 Another observation supporting the contention that a more 
engaged sample was recruited in this trial is the intravenous (IV) antibiotic rejection rate for 
exacerbations among this sample of around 5% (see table S3 footnote), which is four-fold 
lower than in real-world dataset where the IV rejection rate is around 20%.3  
In the CONSORT diagram (figure 2 of main manuscript), we report that 3510 adults with CF 
were screened and 608 were recruited. The discrepancy between screening and recruitment 
was driven by a decision to prioritise rapid recruitment because more than two-thirds of large 
publicly funded trials in the United Kingdom (UK) failed to recruit to time and target.4 As such, 
all adults with CF in participating centres were screened using data from the UK CF registry 
and investigators may have also first approached those they thought would be most amenable 
to participating. Once a centre reached its recruitment target (around 35 participants per 
centre), recruitment for the centre would be closed and a large proportion of other screened 
adults (each centre would have screened on average 150−200 adults) would be unable to 
participate. This strategy has enabled us to recruit 608 participants in just 8 months (even 
though not all centres open for recruitment at the same time), which is ahead of the recruitment 
target.  
Although a biased sample that was more focused on adherence may have been recruited as 
the result of the recruitment strategy, it is important to consider the direction of any resultant 
bias. As is discussed in appendix D, there is a ceiling effect associated with high baseline 
adherence.5,6 It may follow that scope for improvement in adherence in our trial was curtailed 
in the intervention arm by ceiling effects associated with high baseline adherence and nearly 
30% of the participants having baseline adherence >75%. Therefore, any bias associated with 
the recruitment strategy would be towards null effect and the overall adherence difference of 
adjusted mean difference of 9.5 percentage points (95% confidence interval 8.6, 10.4) may 
have been an under-estimate. 
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APPENDIX D Between-group imbalance and baseline adherence 
Table 2 of the main manuscript suggests there may be some imbalance between usual care 
and intervention groups at baseline. The intervention group was around 1 year older (mean 
age 31.1±10.6 years versus 30.3±10.8 years) yet percent predicted forced expiratory volume 
in one second (FEV1) was higher by around 2 (60.7±23.5 versus 58.3±22.6) and annual 
intravenous (IV) antibiotics use was lower by around 3 days (24.2±27.9 days versus 27.7±33.0 
days). This may suggest that the intervention participants had slightly better lung health at 
baseline, which may be due to higher adherence prior to recruitment. Indeed, there is also 
imbalance of “baseline adherence”, that is the objectively-measured effective adherence level 
measured in the first two weeks post randomisation, which was around 9% in favour of the 
intervention group (54.1±33.0% versus 45.5±34.1%).  
In this section, we deal with the following five issues:  
1) Explain how the randomisation process could result in baseline imbalance despite 608 
participants being randomised  
2) Explore the likely impact of age on the baseline adherence  
3) Provide analyses which explore the adherence trajectory for intervention versus usual 
care after minimising the imbalance of baseline adherence  
4) Explore the impact of baseline imbalance in terms of the direction of bias on the 
observed effect size  
5) Explore how these limitations can be minimised to make future trials more efficient 
 
1) The randomisation process 
The imbalance in baseline parameters is likely due to a randomisation process which involved 
two levels of stratification (centre and past-year IV days, as described in Section 9.1 of the 
protocol [available as supplementary material]) which limits the block size. Each centre 
recruited around 35 participants and the aim was to achieve approximately similar numbers of 
usual care and intervention participants in each centre, so that the centre interventionists were 
not overwhelmed by excess number of intervention participants. Thus the play of chance is 
not acting on 608 participants but is acting on a maximum block size of 35 with two levels of 
stratification to randomise participants into usual care and intervention; i.e. the play of chance 
is constrained by limited block size.
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2) Impact of age on the baseline adherence 
The intervention group was around 1 year older. The adherence imbalance at the initial part 
of the trial may in part be influenced by differences in the proportion of participants according 
to age categories. Multiple studies have demonstrated a strong association between the age 
categories (16-18 years, 19–25 years, 26–34 years, ≥35 years) and adherence levels.1,2 The 
usual care arm has an excess of younger participants with lower adherence and the 
intervention arm has an excess of older participants with higher adherence (figure D1). There 
were 27 usual care and 17 intervention participants aged 16–18 years, where the mean 
baseline adherence for 44 participants was 31%. There were 75 usual care and 91 intervention 
participants aged ≥35 years, where the mean baseline adherence for 166 participants was 
62%. By plotting adherence according to age categories, the effect of age imbalance at the 
start of the trial is clearer. There is less adherence imbalance at the start of the trial when 
participants were grouped by age (figure D1) except for the few participants aged 16–18 years 
(n=44, 7%). Some of the baseline adherence imbalance following age stratification may be 
due to the transient effect of enhanced white coat adherence in the intervention group who 
were aware from Day 1 that a planned 3-week meeting with interventionists to review their 
data would occur. This is consistent with the behaviour change technique of feedback used 
as part of the intervention and contrasts with the usual care group who were aware that 
adherence measurement would simply be used for research and neither fed back nor reviewed 
by interventionists. 
 
Figure D1 Adherence curves according to different age categories. 
 
27 usual care; 17 intervention 100 usual care; 101 intervention 
100 usual care; 95 intervention 
75 usual care; 91 intervention 
16–18 years; n=44; baseline adherence 31% 19–25 years; n=201; baseline adherence 43% 
35+ years; n=166; baseline adherence 62% 
26–34 years; n=195; baseline adherence 51% 
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Figure D2 Adherence curves, and mean between-group difference in objectively-measured 
effective adherence, according to baseline adherence. CI, confidence interval; Int-UC, 
intervention minus usual care. 
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3) Explaining the adherence trajectory for intervention versus usual care 
Trial participants in both arms had never previously been monitored with data-logging 
nebulisers and would likely be susceptible to novelty effect and whitecoat adherence at the 
initial part of the trial,3-6 with the consequence that adherence in the first two weeks was 
unrepresentative of their steady-state adherence. Of note, the baseline adherence imbalance 
was discussed in the previous section and was unrelated to novelty effect or white coat 
adherence. It is known that novelty effect and whitecoat adherence are relatively short-lived3-
6 and this is reflected in the initial sharp adherence decline for both arms seen in the study 
(figure 3 of main manuscript; figure D1). Among control participants who did not receive any 
intervention, this decline continued over the next 12 weeks to around 35%, which is the real-
world objective adherence level for inhaled therapies among adults with CF,7,8 and stayed at 
this level until the end of the trial. In the intervention group, the initial rate of decline was similar 
to the controls until the behavioural-change intervention started from Week 3 and adherence 
subsequently improved. It is also important to note that the separation in adherence curves 
between intervention and usual care participants occurred regardless of baseline adherence 
when curves were plotted by adherence categories (figure D2). 
 
 
4) The impact of baseline imbalance on the direction of bias  
There is a ceiling effect associated with high adherence.9,10 Indeed, subgroup analysis 
according to baseline adherence (figure D2) indicates minimal end of study between-group 
difference in objectively-measured effective adherence among those with baseline 
adherence >75%. It is therefore likely that a preponderance of high adherers among the 
intervention group would bias the overall adjusted adherence results towards null effect, i.e. 
the overall adjusted mean difference in objectively-measured effective adherence of 9.5 
percentage points (95% confidence interval 8.6, 10.4) may have been larger had those with 
baseline adherence >75% been excluded.   
  
5) How these limitations can be minimised to make future trials more efficient 
As discussed in the main manuscript, the measurement of “baseline adherence” in the first 
two weeks post randomisation is a limitation of the trial. It would have been ideal to obtain an 
understanding of the study participants’ actual baseline adherence by measuring adherence 
over longer periods prior to randomisation, which may allow white coat adherence among 
adults using data-logging nebulisers for the first time to wear off. The decay of usual care 
participants’ adherence to baseline took approximately 12 weeks, suggesting the importance 
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of providing objective adherence monitoring technology to participants for at least 12 weeks 
before baseline adherence is captured. This would impact time scales for an adherence trial 
and the funding envelope requested. In our subsequent trials, we plan to nest the evaluation 
of adherence interventions within a digital learning health system (ISRCTN14464661) so that 
baseline adherence can be understood prior to randomisation. This has a number of benefits, 
including recruiting participants in whom adherence can be seen to improve from baseline 
(effectively removing the impact of whitecoat adherence) and greater efficiency by avoiding 
the recruitment of potential participants with maximal adherence at baseline. 
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Appendix E Other limitations of the trial 
In the main manuscript, the limitations of using exacerbation as the primary endpoint which 
may bias the result towards null effect and the difficulty of discerning the trajectory of 
intervention effect due to a lack of pre-randomisation steady-state adherence level were 
discussed. In this appendix, we discuss the other limitations of the trial. 
One of the potential limitations is the delivery of both behavioural change and research 
processes by interventionists. The intervention was delivered via CFHealthHub, which was 
unavailable to usual care participants. Mixed-methods process evaluation of our two-centre 
pilot study, which specifically addressed contamination, demonstrated negligible 
contamination among usual care participants.1 Outcome data were objective measures 
unlikely to be biased by interventionists’ data collection.2  
Three other limitations of the trial might bias the observed results towards a null effect. First, 
a convenience sample was recruited with around 30% of the participants having baseline 
adherence >75%, a subgroup in whom an impact on outcome measures would be unlikely, 
rendering the trial less efficient. It is noteworthy that the intravenous (IV) antibiotic rejection 
rate in this trial was around 5% whereas the real-world IV rejection rate is typically four-fold 
higher at around 20%,3 supporting the contention that a more engaged sample was recruited 
in this trial. The ceiling effect among high adherers means that the effect size would have been 
larger if high adherers were excluded (see appendices C and D). With this limitation, any 
observed difference in adherence in the trial could be considered particularly noteworthy. 
Since trial participants may have better health outcomes than non-participants,4 there may 
also be ceiling effect on health outcomes as well as ceiling effect on adherence. If we assume 
the intervention is able to impact people with lower levels of adherence, the outcomes seen in 
this opportunistic sample might have a larger effect size in the whole population where median 
adherence is ~30%. Interestingly, the FEV1 difference did not include unity in the subset of 
participants with adherence <25%. This further supports the assertion that focusing an 
adherence intervention study on participants with lower levels of adherence has the advantage 
of both trial efficiency and increased probability of impacting health outcomes such as FEV1. 
Second, there was a period of server downtime which affected intervention delivery. 
Adherence data were not lost but simply inaccessible during the downtime. Interventions were 
delivered over 80 weeks (9 months for recruitment) and the CFHealthHub server experienced 
a 43-day outage at one point, which delayed the receipt of data to the server such that the 
platform was inaccessible to all participants during this period. Intervention sessions would be 
rescheduled if adherence data were unavailable, meaning that no intervention took place 
during this period. The server hosting infrastructure was improved following the downtime, 
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reducing the likelihood of future issues. Fidelity assessments throughout the trial, which 
required the use of objective adherence data during sessions, showed reassuring scores of 
93–97%. Given the importance of the platform for intervention delivery, unavailability would 
reduce the intervention effectiveness and bias the results towards null effect. However, in the 
spirit of intent-to-treat analysis, we did not make any adjustments to avoid over-estimating 
treatment effect. It is important to emphasise that periods where data transfer was delayed did 
not result in data loss as data were simply backed up and transferred once system transfer 
was restored.   
Third, the trial was underpowered to detect the observed point estimate in forced expiratory 
volume in one second (FEV1). Sample size calculation in table S1 showed that the trial has 
under 80% power to detect a 6 point difference in between-group percent predicted FEV1. The 
observed between-group point estimate of 1.4 in percent predicted FEV1 at 12 months may 
simply be due to chance but is within the range observed for hypertonic saline at 48 weeks.5 
Overall, these four limitations (alongside the limitations of exacerbation as the primary 
outcome) reduced the trial’s ability to demonstrate statistically significant improvements in lung 
health. The significant albeit small difference in body mass index (BMI) with the intervention 
versus usual care should be noted, and higher BMI has shown an association with higher 
FEV1.6 It is possible that FEV1 improvement may emerge gradually over time with longer 
follow-up. 
It is also possible that improvement in health outcomes may not be linearly associated with 
the increase in adherence; for example, there may be both a threshold effect and a ceiling 
effect. The relationship between improvement in treatment adherence and improvement in 
health outcomes among people with CF is relatively unexplored, in part because previous 
adherence trials did not demonstrate improved adherence. Further analyses would be 
performed using the ACtiF dataset to better understand the relationship between adherence 
to chronic therapies and health outcomes. 
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